B2M and graft versus host disease: In contrast to T cells, a notable advantage of allogeneic NK cells is their safe administration without the risk of GVHD, and the B2M knockout strategy has been employed to develop safer and more efficient ‘off‐the‐shelf’ cellular NK cell therapies [38].